Opportunity Cost of Funding Drugs for Rare Diseases

@article{Coyle2014OpportunityCO,
  title={Opportunity Cost of Funding Drugs for Rare Diseases},
  author={Doug Coyle and Matthew C Cheung and Gerald A Evans},
  journal={Medical Decision Making},
  year={2014},
  volume={34},
  pages={1016 - 1029}
}
Background. Both ethical and economics concerns have been raised with respect to the funding of drugs for rare diseases. This article reports both the cost-effectiveness of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and its associated opportunity costs. Methods. Analysis compared eculizumab plus current standard of care v. current standard of care from a publicly funded health care system perspective. A Markov model covered the major consequences of PNH and… 

Figures and Tables from this paper

Importance of Transparency in Assessing the Feasibility of Modeling Rare Disease
TLDR
The valuation of drugs for rare diseases is an important and complex issue and the Coyle model, which consists of 47 distinct health states and at least 34 parameters affecting the transitional probabilities, suggests that many transitional probabilities used in the model are likely dependent on the experience of just a few patients, at best.
The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
TLDR
It is concluded that economic evaluations of ultra-orphan drugs are feasible if pharmacoeconomic modelling is used and quality of studies using a Markov-state-transition or patient-level simulation model is in general good.
Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States.
TLDR
For people with MDR HIV lacking other treatment options, ibalizumab will substantially increase survival when effective and the low number of eligible patients in the United States makes the budget impact relatively small.
Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis
TLDR
Evaluating the cost effectiveness of stiripentol as an adjunctive treatment to clobazam and valproate for treatment of Dravet syndrome from the perspective of the Canadian public healthcare payer found it to be not cost effective.
A systematic review of moral reasons on orphan drug reimbursement
TLDR
The scientific debate should focus less on the question of disease prevalence but rather on how the important variability of different OMPs concerning e.g. target population, cost-effectiveness, level of evidence or mechanism of action could be meaningfully addressed and implemented in Health Technology Assessments.
Evaluating Canadians' Values for Drug Coverage Decision Making.
  • Shirin Rizzardo, N. Bansback, L. Lynd
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2019
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
TLDR
The evaluation of orphan medicines should include multiple criteria to appropriately measure the clinical added value of orphan drugs, and European policies on orphan drugs may be based largely on experiences in THE AUTHORS countries.
A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians, and society, part 2
TLDR
This manuscript reviews principles and provides clinicians with a framework to think about the value of the drugs prescribed for patients with neuromuscular diseases and establishes a value based (benefit/cost) drug pricing framework.
Immunosuppressants in Brazil: underlying drivers of spending trends, 2010–2015
TLDR
Analyzing immunosuppressant expenditure in Brazil, using data from the Federal Procurement System database (SIASG), between 2010 and 2015 may contribute to understand immunosppressant spending trends and the factors that influence them in order to formulate effective cost containment strategies and design optimum drug policy.
Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR
TLDR
DURDs could be viewed as distinct category from an HTA perspective by explicitly defining DURDs based on objective criteria to facilitate the implementation of HTA assessment process that accounts for the issues associated with DURD.
...
...

References

SHOWING 1-10 OF 99 REFERENCES
Orphan drugs and the NHS: should we value rarity?
TLDR
The justifications for special status for rare diseases are examined and whether the cost effectiveness of drugs for rare or very rare diseases should be treated differently from that of other drugs and interventions is asked.
Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach
TLDR
A rate-of-return style model, employing yardsticked cost allocations and a modified two-stage rate of return calculation could be effective in setting a new standard for orphan drugs pricing.
Assessing the economic challenges posed by orphan drugs
TLDR
Whether the standard methods of HTA are adequate for assisting decisions on patient access to and funding of orphan drugs is discussed and a research agenda is outlined to help understand the societal value of orphan Drugs and issues surrounding their development, funding, and use.
Drugs for exceptionally rare diseases: do they deserve special status for funding?
TLDR
Whether ultra-orphan drugs merit special status by considering efficiency, effectiveness and equity criteria is explored, and Mechanisms are discussed for creating a policy that would reduce geographical inequalities in provision across Europe.
An evaluation framework for funding drugs for rare diseases.
  • E. Winquist, C. Bell, D. Coyle
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2012
Population based screening for chronic kidney disease: cost effectiveness study
Objective To determine the cost effectiveness of one-off population based screening for chronic kidney disease based on estimated glomerular filtration rate. Design Cost utility analysis of screening
Rare diseases: Canada’s “research orphans”
  • Samir Gupta
  • Political Science, Medicine
    Open medicine : a peer-reviewed, independent, open-access journal
  • 2012
TLDR
Canada is one of only a few developed countries without a national “orphan drug” program to protect patients with rare diseases from exorbitant drug costs, and public debate concerning government funding for these drugs is periodically stimulated by stories of patients who are deprived of life-sustaining therapies because of cost.
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients
TLDR
Economic analysis suggest deferasirox is cost effective in lower risk, transfusion-dependent, MDS patients, and a cost per QALY below £20,000–30,000 is considered cost effective.
Pricing and reimbursement of orphan drugs: the need for more transparency
  • S. Simoens
  • Medicine, Political Science
    Orphanet journal of rare diseases
  • 2011
TLDR
There is a need for a transparent and evidence-based approach towards orphan drug pricing and reimbursement that is targeted at demonstrating the relative effectiveness, cost-effectiveness and economic viability of orphan drugs with a view to informing Pricing and reimbursement decisions.
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
TLDR
The methods go some way to providing an empirical estimate of the scale of opportunity costs the NHS faces when considering whether or not the health benefits associated with new technologies are greater than the health that is likely to be lost elsewhere in the NHS.
...
...